Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study
Se Young Choi
BackgroundThe incidence and mortality of renal cell carcinoma (RCC) exhibit marked sex-based differences, suggesting a potential role for androgen signaling in disease progression. Although 5α-reductase inhibitors (5-ARIs) are widely prescribed for benign prostatic conditions, their potential association with survival in patients with RCC remains poorly understood. We evaluated the association between long-term use of 5-ARIs and overall survival in men with RCC.MethodsThis population-based retro